Preeclampsia
Conditions
Keywords
Preeclampsia, EG-VEGF, Prokineticin, cesarean, placenta pathological examination, pregnancy, PROK1 receptor, PROKR2 receptor
Brief summary
The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors. A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor) also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE. EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2 team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA Grenoble) demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is directly involved in the development of Pre-Eclampsia. Few studies have evaluated the expression of EG-VEGF in the human placenta.
Interventions
BIOLOGICALPlacenta pathological examination
a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
Sponsors
Commissariat A L'energie Atomique
Centre Hospitalier Universitaire de Saint Etienne
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital. * For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia * For the control group: patient who had a normal pregnancy
Exclusion criteria
* Patient who gave birth naturally * Underage patients or under guardianship * Patients who do not speak or read French * Childbirth under X
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry | At delivery | Measured by placenta pathological examination (immunohistochemistry technical). |
| Quantification of EG-VEGF staining (ImageJ®) by immunohistochemistry | At delivery | Measured by placenta pathological examination (immunohistochemistry technical). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immuno-localization of the staining of PROKR2 (ImageJ®) by immunohistochemistry | At delivery | Measured by placenta pathological examination (immunohistochemistry technical). |
| Quantification of the staining of PROKR2 (ImageJ®) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical). | At delivery | Measured by placenta pathological examination (immunohistochemistry technical). |
| Immuno-localization of the staining of PROKR1 (ImageJ®) by immunohistochemistry | At delivery | Measured by placenta pathological examination (immunohistochemistry technical). |
| Obstetric history | At delivery | Pre-Eclampsia (PE) and intra uterine growth retardation (IUGR), term of onset and severity of Pre-Eclampsia (PE) |
| Presence of an anticoagulant treatment | At delivery | treatment by aspirin or Heparin or low molecular weight heparins (LMWH) |
| Presence of at least one chronic maternal pathologies describe below | At delivery | diabetes, hypertension, kidney disease, Systemic Lupus Erythematosus (SLE), antiphospholipid syndrome |
| Quantification of the staining of PROKR1 (ImageJ®) by immunohistochemistry | At delivery | Measured by placenta pathological examination (immunohistochemistry technical). |
Countries
France
Outcome results
None listed